Evidence map›Paper›PMID 38355706›Full record

ArticleAlzheimer's research & therapy2024

Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis.

Pierre N Tariot, Mercè Boada, Krista L Lanctôt, Julie Hahn-Pedersen, Firas Dabbous, Sariya Udayachalerm, Lars Lau Raket, Yuliya Halchenko, Wojciech Michalak, Wendy Weidner and 1 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Cross-dataset Evaluation of Dementia Longitudinal Progression Prediction Models.medRxiv : the preprint server for health sciences · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 6 countries.

Pierre N TariotBanner Alzheimer's Institute, Phoenix, AZ, 85006, USA. pierre.tariot@bannerhealth.com.
Mercè BoadaAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, 08028, Barcelona, Spain.
Krista L LanctôtSunnybrook Research Institute, Toronto, ON, M4N 3M5, Canada.
Julie Hahn-PedersenNovo Nordisk A/S, 2860, Søborg, Denmark.
Firas Dabbous, Evidera, Bethesda, MD, 20814, USA.
Sariya Udayachalerm, Evidera, Bethesda, MD, 20814, USA.
Lars Lau RaketNovo Nordisk A/S, 2860, Søborg, Denmark.
Yuliya Halchenko, Evidera, Bethesda, MD, 20814, USA.
Wojciech MichalakNovo Nordisk A/S, 2860, Søborg, Denmark.
Wendy WeidnerAlzheimer's Disease International, London, SE1 4PU, UK.
Jeffrey CummingsChambers-Grundy Center for Transformative Neuroscience, UNLV, Las Vegas, NV, 89154, USA.
Ithaka Harbors · USNovo Nordisk (Denmark) · DKAlzheimer Disease International · GBBanner Alzheimer’s InstituteInstituto de Salud Carlos III · ESLou Ruvo Brain Institute · USSunnybrook Health Science Centre · CA

Funding

NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's DiseaseR01AG053798 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., CUMMINGS, JEFFREY L. · 2017 to 2022
$39.4M
Translational and Therapeutics CoreP30AG072959 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Mark J Lowe · 2021 to 2026
$23.9M
Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI JESSICA KIRKLAND CALDWELL · 2015 to 2026
$22.8M
NVEDARC Clinical CoreP20AG068053 · NIA · CLEVELAND CLINIC FOUNDATION · PI FOX, ROBERT J. · 2020 to 2022
$3.3M
Alzheimer's Clinical Trial InnOvatioN (ACTION) InitiativeR35AG071476 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI CUMMINGS, JEFFREY L. · 2021 to 2025
$2.9M
NIA NIH HHS P20 AG068053NIA NIH HHS P30 AG072959NIA NIH HHS R01 AG053798NIA NIH HHS R35 AG071476NIA NIH HHS U01 AG016976NIGMS NIH HHS P20 GM109025
6 · The paper itself

Abstract

backgroundUnderstanding the relationship among changes in Clinical Dementia Rating (CDR), patient outcomes, and probability of progression is crucial for evaluating the long-term benefits of disease-modifying treatments. We examined associations among changes in Alzheimer's disease (AD) stages and outcomes that are important to patients and their care partners including activities of daily living (ADLs), geriatric depression, neuropsychiatric features, cognitive impairment, and the probabilities of being transitioned to a long-term care facility (i.e., institutionalization). We also estimated the total time spent at each stage and annual transition probabilities in AD.

methodsThe study included participants with unimpaired cognition, mild cognitive impairment (MCI) due to AD, and mild, moderate, and severe AD dementia in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS) database. The associations among change in AD stages and change in relevant outcomes were estimated using linear mixed models with random intercepts. The probability of transitioning to long-term care facilities was modeled using generalized estimating equations. The total length of time spent at AD stages and annual transition probabilities were estimated with multistate Markov models.

resultsThe estimated average time spent in each stage was 3.2 years in MCI due to AD and 2.2, 2.0, and 2.8 years for mild, moderate, and severe AD dementia, respectively. The annual probabilities of progressing from MCI to mild, moderate, and severe AD dementia were 20, 4, and 0.7%, respectively. The incremental change to the next stage of participants with unimpaired cognition, MCI, and mild, moderate, and severe AD dementia (to death) was 3.2, 20, 26.6, 31, and 25.3%, respectively. Changes in ADLs, neuropsychiatric features, and cognitive measures were greatest among participants who transitioned from MCI and mild AD dementia to more advanced stages. Participants with MCI and mild and moderate AD dementia had increasing odds of being transitioned to long-term care facilities over time during the follow-up period.

conclusionsThe findings demonstrated that participants with early stages AD (MCI or mild dementia) were associated with the largest changes in clinical scale scores. Early detection, diagnosis, and intervention by disease-modifying therapies are required for delaying AD progression. Additionally, estimates of transition probabilities can inform future studies and health economic modeling.

Indexed as

Alzheimer DiseaseCognitive DysfunctionDementiaActivities of Daily LivingAgedDisease ProgressionHumansMental Status and Dementia TestsProbabilityActivities of daily livingAlzheimer’s diseaseBurdenClinical Dementia RatingCognitive impairmentInstitutionalizationLong-term care facilityNeuropsychiatric featuresProgressionTransition probabilities

Identifiers

PMID38355706
PMCPMC10868090
OpenAlexW4391841703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.